Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with LGMDs drug development. LGMDs are a group of disorders that affect voluntary muscles, primarily those around the hips and shoulders.
The confirmed members of the task force include ML Bio Solutions, the Coalition to Cure Calpain 3, the CureLGMD2i Foundation, the Jain Foundation, the LGMD2D Foundation, the LGMD2i Research Fund, and The Speak Foundation. Additionally, collaborations are underway with key thought leaders and patient advocacy groups to ensure comprehensive stakeholder engagement. This task force will leverage the collective expertise of its members to expedite the development of new treatments for LGMDs.
By integrating patient-level data from diverse sources through C-Path's RDCA-DAP -; an FDA-funded initiative that provides a centralized and standardized infrastructure to support and accelerate rare disease characterization -; the task force will work to identify and address the critical gaps in LGMDs research and development. The collaboration provides a neutral platform for stakeholders from industry, regulatory agencies, academia, and the LGMDs community to engage in meaningful .